Home > Products > Brezofil
Share Print This Page

Brezofil (Doxofylline)
Therapeutic Group: Respiratory » Anti Asthmatics » Bronchodilator

Brezofil: Each tablet contains Doxofylline INN 400 mg.

Doxofylline, a new generation xanthine belonging to a new class of drug referred to as Novofylline, which is chemically 1,3-dimethyl-3,7-dihydro-purine-2,6-dione. Its molecular formula is C11H14N4O4 and its molecular weight is 266.253 g/mol. Doxofylline is a new creation long lasting oral methylxanthine extract. Methylxanthines are from the family of phosphodiesterase inhibitors. Correspondingly, its system of activity is associated to the reticence of phosphodiesterase action, initiating in bronchodilating actions. It has a bronchodilator effect which reduces rate of breathlessness in patients suffering from asthma. It helps relax the muscles in the bronchi and bronchioles, thus causing dilatation of the air passages and helping patients to breathe easily. The drug also possesses antitussive properties which help to control the cough linked with lung disorders.
Doxofylline is mostly administered for maintenance treatment in subjects experiencing COPD (Chronic Obstructive Pulmonary Disease) and bronchial asthma. Doxofylline is not designed for use as an emergency treatment during an asthma attack.
Dosage & Administration
Adults: 1 to 3 times a day as the prescription of a physician. Dosage of Doxofylline depends on patient’s response to the medication. If a patient has been advised to dose once a day, he or she may be directed to do so in the evenings to reduce nocturnal symptoms.
Elderly: The dosage may be decreased according to medical prescription in the very elderly patients with concomitant cardiovascular, hepatic, renal and gastric disease, to ½ tablet b.i.d/ t.i.d.
Child: Children >12 years – 200 mg 2 or 3 times daily. (½ tablet b.i.d/ t.i.d)
Side Effects
After xanthine administration, nausea, vomiting, epigastric pain, cephalalgia, irritability, insomnia, tachycardia, extrasystole, tachypnea and occasionally, hyperglycemia and albuminuria, may occur. If a potential oral overdose is established, the patient may present with severe arrhythmias and seizure; these symptoms could be the first sign of an intoxication. Adverse reactions may cause the withdrawal from treatment; a lower dose rechallenge may start only after the advice of a physician.
Use with caution in patients with hypoxemia, hyperthyroidism, liver disease, renal disease, in those with history of peptic ulcer and in elderly. Frequently, patients with Congestive Heart Failure (CHF) have markedly prolonged drug serum levels following discontinuation of Doxofylline.
This is contraindicated for individuals who have shown hypersensitivity to Doxofylline and its components. It is also contraindicated in patients with acute myocardial infarction, hypotension, and in lactating women.
Use in Pregnancy & Lactation
Animal reproduction studies indicate that Doxofylline does not cause fetal harm when administered to pregnant animals nor can affect reproduction capacity. However, since there is limited experience in human during pregnancy, xanthines should be given to a pregnant woman only if clearly needed.
Drug Interaction
Doxofylline should not be administered together with other xanthine derivatives. Toxic synergism with ephedrine has been documented for xanthines. Like other xanthines, concomitant therapy with erythromycin. troleandomycin, lincomycin, clindamycin, allopurinol, cimetidine, ranitidine, propranolol and anti-flu vaccine may decrease the hepatic clearance of xanthines causing an increase in blood levels. No evidence of a relationship between Doxofylline serum concentrations and toxic events have been reported.
Although no major arrhythmias have been documented with Doxofylline, the occurrence of major cardiac rhythm disturbances cannot be excluded in case of overdosage of xanthine compounds. If a potential oral overdose is established, the patient may present with seizures; this symptom could be the first sign of intoxication. Adverse reactions may cause withdrawal from treatment.
- Store at room temperature (not exceeding 25°C).
- Store in cool and dry place, protected from light.
Commercial Packaging
Brezofil: Each box contains 3 blister strips of 10 tablets.
Products from the same therapeutic group
Anti Asthmatics
Theophylline BP 300 mg & 400 mg sustained release tablet
Levosalbutamol Sulphate INN
Salbutamol Sulphate BP
Purisal Nebuliser Solution
Levosalbutamol Hydrochloride INN
Windel Plus
Salbutamol/Ipratropium Bromide
Ipratropium Bromide BP
Roflumilast 0.5 mg (500 mcg) Tablet
Budemet ConviCap
Budesonide and Formoterol Fumarate Dihydrate Convicap
Flutisal ConviCap
Fluticasone Propionate BP and Salmeterol Xinafoate BP inhalation powder.
Windel ConviCap
Salbutamol Sulphate BP inhalation powder.
Doxofylline INN Tablet
Leukotriene Receptor Antagonist
Montelukast Tablet
Steroidal Preparation
Cough Suppressant
Expectorant Syrup
Butamirate Citrate INN
Glycerol and Liquid Sugar 100 ml Syrup
Antitussive syrup
Dextromethorphan syrup
Drugs for Allergic Rhinitis
Nasal Steroidal Preparation
Momeson Nasal Spray
Mometasone Furoate BP
Budicort Nasal Spray
Budesonide BP
Lutisone Nasal Spray
Fluticasone Propionate BP
Fluticasone Furoate Nasal Spray
Antihistamine Preparation
Triamcinolone Acetonide BP Nasal Spray
Lopadine Nasal Spray
Olopatadine Hydrochloride INN
Mast Cell Stabiliser
Nasal Decongestant & Mast Cell Combination
Oxymetazoline Hydrochloride
Xylo Plus
Xylometazoline Hydrochloride BP and Sodium Cromoglicate BP
Mucolytic Expectorant
Ambroxol hydrochloride
Mucolytic Expectorant